Summarize this content material to 1000 phrases
(HealthDay Information) — Practically half of Veterans Well being Administration (VA) sufferers with treatment-resistant despair who obtained intravenous (IV) ketamine noticed a significant drop in despair scores by the top of six weeks of infusions, in response to a examine revealed on-line Jan. 8 in The Journal of Medical Psychiatry.
Paul N. Pfeiffer, MD, from the College of Michigan Medical College in Ann Arbor, and colleagues used information from the VA digital medical data for 215 sufferers handled with IV ketamine infusions for despair in fiscal 12 months 2020, with as much as 12 months of follow-up.
The researchers discovered that individuals had a imply of two.1 antidepressant treatment trials up to now 12 months and 6.1 antidepressant trials within the 20 years previous to their first ketamine infusion. In the course of the first 5 months of infusions, frequency of infusions decreased from each 5 days to each three to 4 weeks, with a imply of 18 whole infusions over 12 months. After six weeks of therapy, 26% of individuals had a response (50% enchancment within the Affected person Well being Questionnaire-9 [PHQ-9] rating) and 15% had remission (PHQ-9 rating ≤5). At weeks 12 and 26, these enhancements had been comparable. There have been no associations between demographic traits and comorbid diagnoses with six-week PHQ-9 scores.
“These findings ratchet down the hype about ketamine a bit, as a result of we don’t see dramatic enchancment after only one infusion, or sturdy response in most sufferers,” Pfeiffer mentioned in a press release. “It’s not a silver bullet. However once we see these sufferers in our clinic, who’ve been by way of each therapy accessible and nothing has labored, to have even 1 / 4 obtain a major measurable response is excellent.”
Summary/Full Textual content (subscription or fee could also be required)